Genentech executive urges pharma omnichannel strategies to bypass 60-second linear ads

The shift toward claim-free creative signals a major transition for CTV platforms, which have historically struggled to accommodate lengthy pharmaceutical risk disclosures. By decoupling brand sentiment from specific medical claims, pharmaceutical companies can finally deploy high-frequency, short-form video that aligns with digital consumption habits rather than legacy linear constraints. This move forces a competitive realignment as traditional broadcasters lose their grip on high-margin pharma budgets to programmatic CTV and social video environments. As digital spending overtakes linear by nearly four-to-one, the industry must watch for updated FDA guidance regarding how 'fair balance' rules apply to non-linear, claim-free branding.

Pharmaceutical advertising has become one of the fastest-growing verticals in connected TV, with major brands reallocating budgets from linear to digital environments. In early 2026, eMarketer projected that US pharma digital ad spending would reach $26.4 billion in 2026, up from $22.1 billion the prior year, with CTV and online video accounting for the largest share of that growth. Genentech's parent company Roche has been among the most aggressive adopters, running programmatic CTV campaigns for brands like Ocrevus and Hemlibra that rely on short-form, claim-free creative to avoid the lengthy risk disclosures required for product-specific claims. This mirrors the broader trend Marc Minassian described, where pharma marketers treat CTV as a brand-building channel rather than a direct-response vehicle.

The regulatory landscape governing pharma advertising continues to evolve alongside these budget shifts. In May 2025, the FDA issued draft guidance clarifying how fair-balance requirements apply to digital and social media formats, acknowledging that character-limited platforms and short-form video present unique challenges for including risk information. The guidance suggested that claim-free branding, which does not reference a specific indication or benefit, may not trigger the same disclosure obligations as product claims. Separately, the Association of National Advertisers reported in a March 2026 survey that 71% of pharma marketers had increased their CTV budgets year-over-year, citing improved measurement and the ability to test multiple creative lengths against a single audience segment.

On the technical and measurement side, CTV platforms have been building pharma-specific capabilities to capture these budgets. In April 2026, Innovid announced a partnership with Veeva Systems to enable compliant pharma creative trafficking and approval workflows directly within its CTV ad-serving platform, reducing the time from regulatory review to campaign launch. Meanwhile, iSpot.tv reported that pharma brands accounted for 18% of all CTV ad impressions measured on its platform in Q1 2026, up from 12% a year earlier, with 6-second and 15-second spots representing the fastest-growing format category. These infrastructure investments suggest that the CTV ad spending growth Minassian advocates is no longer experimental but is becoming the default operating model for pharmaceutical video advertising.